Canada - English
Canada - Français
For a refined risk estimateof local recurrence
Primary study group results were presented at ASCO 2018.
Help Stage II colon cancer patients understand the power of genomics
In a large clinical data setGPS increased AS utilzation
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test.
American Society of Clinical Oncology's Annual Meeting
May 31 – June 4, 2019 | Chicago, IL | McCormick Place | Booth 12097
The newly designed report provides 3 points of clarity to aid in treatment decisions.
Medicare coverage now provides metastatic castration-resistant prostate cancer (mCRPC) patients access to more definitive treatment options.
Have a specific question? Want to keep up with our latest news? We're here for you.